Prescribing Patterns of Continuous Infusions in Nonobese versus Obese Children Admitted to the Pediatric Intensive Care Unit

Abstract

This retrospective study compared the continuous infusions prescribed for obese and nonobese children. Ninety-five (13.2%) received an infusion. A greater percentage of obese (n = 42/168) versus nonobese (53/552) children received infusions, p < 0.01. No difference was noted in the median number of infusions between the obese and nonobese groups, 2 versus 2, p = 0.975. The top 20 prescribed infusions included ten (50%) for sedation/analgesia or neuromuscular blockade and six (30%) for hemodynamic support. A literature search was performed for these 20 agents to determine pharmacokinetics, pharmacodynamics, and dosing in obese children and revealed six studies evaluating fentanyl (n = 2), midazolam (n = 1), and propofol (n = 3).

Keywords

obesity - children - pharmacokinetics

• References

• 1 Ogden CL, Fryar CD, Hales CM, Carroll MD, Aoki Y, Freedman DS. Differences in obesity prevalence by demographics and urbanization in US children and adolescents, 2013–2016. JAMA 2018; 319 (23) 2410-2418
• 2 Johnson PN, Miller JL, Hagemann TM, Moffett BS. Assessment of inpatient admissions and top 25 medications for obese pediatric patients at two academic hospitals. Am J Health Syst Pharm 2016; 73 (16) 1243-1249
• 3 Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet 2000; 39 (03) 215-231
• 4 Pai MP, Bearden DT. Antimicrobial dosing considerations in obese adult patients. Pharmacotherapy 2007; 27 (08) 1081-1091
• 5 Kendrick JG, Carr RR, Ensom MH. Pharmacokinetics and drug dosing in obese children. J Pediatr Pharmacol Ther 2010; 15 (02) 94-109
• 6 Miller JL, Johnson PN, Harrison DL, Hagemann TM. Evaluation of inpatient admissions and potential antimicrobial and analgesic dosing errors in overweight children. Ann Pharmacother 2010; 44 (01) 35-42
• 7 Ross EL, Heizer J, Mixon MA. , et al. Development of recommendations for dosing of commonly prescribed medications in critically ill obese children. Am J Health Syst Pharm 2015; 72 (07) 542-556
• 8 Ritzmo C, Söderhäll S, Karlén J, Nygren H, Eksborg S. Pharmacokinetics of doxorubicin and etoposide in a morbidly obese pediatric patient. Pediatr Hematol Oncol 2007; 24 (06) 437-445
• 9 Hijiya N, Panetta JC, Zhou Y. , et al. Body mass index does not influence pharmacokinetics or outcome of treatment in children with acute lymphoblastic leukemia. Blood 2006; 108 (13) 3997-4002
• 10 Miller M, Miller JL, Hagemann TM, Harrison D, Chavez-Bueno S, Johnson PN. Vancomycin dosage in overweight and obese children. Am J Health Syst Pharm 2011; 68 (21) 2062-2068
• 11 Lewis TV, Johnson PN, Nebbia AM, Dunlap M. Increased enoxaparin dosing is required for obese children. Pediatrics 2011; 127 (03) e787-e790
• 12 Johnson PN, Benefield EC, Bui PY, Marlar RA, Gessouroun MR. Fondaparinux in an obese child with heparin-induced thrombocytopenia and a history of renal failure. J Pediatr Pharmacol Ther 2013; 18 (04) 303-310
• 13 Moffett BS, Kim S, Edwards MS. Vancomycin dosing in obese pediatric patients. Clin Pediatr (Phila) 2011; 50 (05) 442-446
• 14 Choi JJ, Moffett BS, McDade EJ, Palazzi DL. Altered gentamicin serum concentrations in obese pediatric patients. Pediatr Infect Dis J 2011; 30 (04) 347-349
• 15 Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. Anesthesiology 1992; 76 (03) 334-341
• 16 Centers for Disease Control and Prevention. Defining childhood overweight and obesity. Available at: www.cdc.gov/obesity/childhood/defining.html . Accessed April 26, 2019
• 17 BMI Percentile Calculator for Child and Teen. CDC. Available at: https://www.cdc.gov/healthyweight/bmi/calculator.html . Accessed April 26, 2019
• 18 Gish EC, Harrison D, Gormley AK, Johnson PN. Dosing evaluation of continuous intravenous fentanyl infusions in overweight children: a pilot study. J Pediatr Pharmacol Ther 2011; 16 (01) 39-46
• 19 Johnson PN, Skrepnek GH, Golding CL, Owora AH, Thomas AN, Miller JL. Relationship between rate of fentanyl infusion and time to achieve sedation in nonobese and obese critically ill children. Am J Health Syst Pharm 2017; 74 (15) 1174-1183
• 20 van Rongen A, Vaughns JD, Moorthy GS, Barrett JS, Knibbe CA, van den Anker JN. Population pharmacokinetics of midazolam and its metabolites in overweight and obese adolescents. Br J Clin Pharmacol 2015; 80 (05) 1185-1196
• 21 Diepstraten J, Chidambaran V, Sadhasivan S. , et al. Propofol clearance in morbidly obese children and adolescents. Clin Pharmacokinet 2012; 51: 543-551
• 22 Chidambaran V, Sadhasivam S, Diepstraten J. , et al. Evaluation of propofol anesthesia in morbidly obese children and adolescents. BMC Anesthesiol 2013; 13 (08) 8 . doi: 10.1186/1471-2253-13-8
• 23 Chidambaran V, Venkatasubramanian R, Sadhasivam S. , et al. Population pharmacokinetic-pharmacodynamic modeling and dosing simulation of propofol maintenance anesthesia in severely obese adolescents. Paediatr Anaesth 2015; 25 (09) 911-923
• 24 Stephens K, Bergeron E, Barker P. , et al. Comparison of clinical outcomes and medication exposure of obese versus non-obese children admitted to the pediatric intensive care unit. J Pediatr Pharmacol Ther 2018; 23: 255-256
• 25 Callaghan LC, Walker JD. An aid to drug dosing safety in obese children: development of a new nomogram and comparison with existing methods for estimation of ideal body weight and lean body mass. Anaesthesia 2015; 70 (02) 176-182
• 26 Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44 (10) 1051-1065
• 27 Bartelink IH, Rademaker CM, Schobben AF, van den Anker JN. Guidelines on paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations. Clin Pharmacokinet 2006; 45 (11) 1077-1097
• 28 Shibutani K, Inchiosa Jr MA, Sawada K, Bairamian M. Accuracy of pharmacokinetic models for predicting plasma fentanyl concentrations in lean and obese surgical patients: derivation of dosing weight (“pharmacokinetic mass”). Anesthesiology 2004; 101 (03) 603-613
• 29 Shibutani K, Inchiosa Jr MA, Sawada K, Bairamian M. Pharmacokinetic mass of fentanyl for postoperative analgesia in lean and obese patients. Br J Anaesth 2005; 95 (03) 377-383
• 30 Droege CA, Ernst NE, Murthy MS, Shuman CS. Impact of norepinephrine weight-based dosing compared with non-weight-based dosing in achieving time to goal mean arterial pressure in obese patients with septic shock. Ann Pharmacother 2017; 51 (07) 614-616
• 31 Radosevich JJ, Patanwala AE, Erstad BL. Norepinephrine dosing in obese and nonobese patients with septic shock. Am J Crit Care 2016; 25 (01) 27-32
• 32 Hodge EK, Hughes DW, Attridge RL. Effect of body weight on hemodynamic response in patients receiving fixed-dose vasopressin for septic shock. Ann Pharmacother 2016; 50 (10) 816-823
• 33 Landry DW, Levin HR, Gallant EM. , et al. Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997; 95 (05) 1122-1125
• 34 Patel BM, Chittock DR, Russell JA, Walley KR. Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002; 96 (03) 576-582
• 35 Kim TK, Obara S, Egan TD. , et al; the Remifentanil Pharmacokinetics in Obesity Investigators. Disposition of remifentanil in obesity: a new pharmacokinetic model incorporating the influence of body mass. Anesthesiology 2017; 126 (06) 1019-1032
• 36 Egan TD, Huizinga B, Gupta SK. , et al. Remifentanil pharmacokinetics in obese versus lean patients. Anesthesiology 1998; 89 (03) 562-573
• 37 La Colla L, Albertin A, La Colla G. , et al. Predictive performance of the ‘Minto’ remifentanil pharmacokinetic parameter set in morbidly obese patients ensuing from a new method for calculating lean body mass. Clin Pharmacokinet 2010; 49 (02) 131-139
• 38 Leykin Y, Pellis T, Lucca M, Lomangino G, Marzano B, Gullo A. The effects of cisatracurium on morbidly obese women. Anesth Analg 2004; 99 (04) 1090-1094
• 39 Salihoĝlu Z, Demiroluk S, Köse Y, Zengin K, Taskin M, Gökay BV. Neuromuscular effects of cisatracurium in morbidly obese patients. Middle East J Anaesthesiol 2008; 19 (04) 831-839
• 40 Schwartz AE, Matteo RS, Ornstein E, Halevy JD, Diaz J. Pharmacokinetics and pharmacodynamics of vecuronium in the obese surgical patient. Anesth Analg 1992; 74 (04) 515-518
• 41 Weinstein JA, Matteo RS, Ornstein E, Schwartz AE, Goldstoff M, Thal G. Pharmacodynamics of vecuronium and atracurium in the obese surgical patient. Anesth Analg 1988; 67 (12) 1149-1153
• 42 de Hoogd S, Välitalo PAJ, Dahan A. , et al. Influence of morbid obesity on the pharmacokinetics of morphine, morphine 3-glucoronide, and morphine-6-glucoronide. Clin Pharmacokinet 2017; 56 (12) 1577-1587
• 43 Xu B, Zhou D, Ren L, Shulman S, Zhang X, Xiong M. Pharmacokinetic and pharmacodynamics of intravenous dexmedetomidine in morbidly obese patients undergoing laparoscopic surgery. J Anesth 2017; 31 (06) 813-820
• 44 Cortínez LI, Anderson BJ, Holford NH. , et al. Dexmedetomidine pharmacokinetics in the obese. Eur J Clin Pharmacol 2015; 71 (12) 1501-1508
• 45 Lim SY, Woo S, Miller JL, Lewis TV, Henry ED, Johnson PN. Dosing for fentanyl infusion in obese children: just because it's what we have always done doesn't mean it is right. J Pediatr Pharmacol Ther 2018; 23 (03) 223-226